SIGHT SCIENCES INC
SGHT · NASDAQ
Updated at 2026-10-15 08:07:21
- Today's High
- $8.65
- Today’s Low
- $8.21
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $8.21
- Previous Close
- $8.25
- Volume
- 304.67K
- Market Cap
- $454.47M
- P/E Ratio
- --
- EPS
- $-0.55
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Health Care
- Sub-industry
- MEDICAL DEVICES
- Headquarters
- 4040 CAMPBELL AVENUE, MENLO PARK, CA, UNITED STATES, 94025
- Country
- US
- Listing Date
- 2021-07-15
- Fiscal Year End
- December
- Shares Outstanding
- 54.41M
- CIK
- 0001531177
- Website
- www.sightsciences.com
Sight Sciences Inc. (SGHT) is an innovative medical technology company specializing in the advancement of treatments for ocular diseases, with a particular emphasis on glaucoma management through both surgical and non-surgical approaches. The company’s diverse product portfolio, supported by a robust intellectual property framework, positions it favorably as demand for minimally invasive ophthalmic therapies escalates. By focusing on enhancing patient outcomes and refining its distribution network, Sight Sciences is set to capture significant market share in the evolving healthcare landscape, making it a noteworthy opportunity for institutional investors seeking growth in the medical technology sector.
Financial Metrics
Revenue
2026-06-30
$23.38M
2026-03-31
$19.69M
2025-12-31
$20.38M
2025-09-30
$19.9M
Operating Expenses
2026-06-30
$25.26M
2026-03-31
$29.39M
2025-12-31
$21.45M
2025-09-30
$25.1M
Net Income
2026-06-30
-$4.44M
2026-03-31
-$12.98M
2025-12-31
-$4.16M
2025-09-30
-$8.16M
Net Profit Margin
2026-06-30
-19%
2026-03-31
-65.89%
2025-12-31
-20.41%
2025-09-30
-41.03%
Earnings Per Share
2026-06-30
$-0.08
2026-03-31
$-0.24
2025-12-31
$-0.08
2025-09-30
$-0.16
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$4.55M
2026-03-31
-$11.59M
2025-12-31
-$2.75M
2025-09-30
-$6.83M
Effective Tax Rate
2026-06-30
-0.63%
2026-03-31
-0.08%
2025-12-31
-0.19%
2025-09-30
0.95%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $23.38M | $19.69M | $20.38M | $19.9M |
| Operating Expenses | $25.26M | $29.39M | $21.45M | $25.1M |
| Net Income | -$4.44M | -$12.98M | -$4.16M | -$8.16M |
| Net Profit Margin | -19% | -65.89% | -20.41% | -41.03% |
| Earnings Per Share | $-0.08 | $-0.24 | $-0.08 | $-0.16 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$4.55M | -$11.59M | -$2.75M | -$6.83M |
| Effective Tax Rate | -0.63% | -0.08% | -0.19% | 0.95% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.